Loading clinical trials...
Loading clinical trials...
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT07083011 · Heart Failure With Preserved Ejection Fraction
NCT07550790 · Heart Failure Acute, Renal Dysfunction
NCT07037459 · Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, and more
NCT06148935 · Chronic Heart Failure With Reduced Ejection Fraction
NCT06874556 · Heart Failure
Novartis Investigative Site
Calgary, Alberta
Novartis Investigative Site
Calgary, Alberta
Novartis Investigative Site
Edmonton, Alberta
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions